OVERVIEW

Immunogenicity Risk Assessment for Nucleic Acid Therapeutics is organized by Oligonucleotide Therapeutics Society (OTS) and will be held on Sep 24, 2026.

Description:
Nucleic acid therapeutics require new immunogenicity evaluation frameworks, as the safety and efficacy of these therapies can be impacted by immune responses triggered by different molecular components of these drugs (ASO, siRNA, and non-vaccine mRNA/LNP). This webinar will cover recommendations on conducting immunogenicity risk assessments and developing the right monitoring strategies to get these therapies safely to patients.